Healthcare Providers and Services
Company Overview of ParagonRx International, LLC
ParagonRx International, LLC provides pharmaceutical risk management and optimizing medication use services for biopharmaceutical, pharmaceutical, and biotech companies. It offers risk management and REMS services, such as evidence-based analysis, REMS planning and design, regulatory preparations, implementation readiness, and operations and assessment services to support the strategy, design, development, documentation, approval, and implementation of risk management programs. The company also provides optimal product use services, including market landscape assessment, observational research, patient care process mapping, and product adoption programs; and strategic planning, organizationa...
2751 Centerville Road
Little Falls Centre Two
Wilmington, DE 19808
Founded in 2001
Key Executives for ParagonRx International, LLC
Co-Founder, Chief Executive Officer, President and Principal
Co-Founder, Principal and Chief Medical Officer
Chief Executive Officer of InVentiv Health
Clinical Services Director
Compensation as of Fiscal Year 2015.
ParagonRx International, LLC Key Developments
ParagonRx Appoints Stephen W. Sun, MD, MPH as Chief Medical Officer
Aug 22 13
ParagonRx announced the appointment of Stephen W. Sun, MD, MPH, as Chief Medical Officer advising clients on regulatory and safety issues. The company reported that Dr. Sun, formerly with the U.S. Food and Drug Administration (FDA), will be reporting directly to ParagonRx President Jeffrey Fetterman. His appointment comes at a time of dramatic regulatory change in both the United States and globally. Regulators are under pressure to speed review of new medical products while simultaneously improving safety. As a consequence, drug developers and device makers planning for a successful review must be proactive in assuring optimal and safe use of products before the products come up for review. ParagonRx clients will have access to a savvy regulatory strategist in Dr. Sun, who understands the escalating scientific rigor regulators expect to see in filings. His public health experience also will benefit clients seeking counsel on the appropriate use of medications and devices designed to improve the well-being of large populations. After King Pharmaceuticals' acquisition of Alpharma, Dr. Sun served as King's Senior Director of Pharmacovigilance and Risk Management before moving on to further expand his industry experience in over-the-counter medications at Reckitt-Benckiser.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries